Preservation of myocardial functions by pentoxyphylline cardioplegia during and after cardiopulmonary bypass

Panminerva Medica

Volumn 42, Issue 4, 2000, Pages 253-256

  Ulus, A T ^b   Aksoyek A ^b   Katircioglu S F ^b   Gokce P ^a   Koc B ^a  

^a ANKARA UNIVERSITY   (Turkey)

^b ulus Apt ^*

Author keywords

Cardioplegic solutions; Cardiopulmonary bypass; Dogs; Reperfusion injury

Indexed keywords

PENTOXIFYLLINE;

ANIMAL; ARTICLE; CARDIOPULMONARY BYPASS; DOG; DRUG EFFECT; HEART; HEART ARREST; HEMODYNAMICS; PATHOPHYSIOLOGY; REPERFUSION INJURY;

ANIMALS; CARDIOPULMONARY BYPASS; DOGS; HEART; HEART ARREST, INDUCED; HEMODYNAMIC PROCESSES; MYOCARDIAL REPERFUSION INJURY; PENTOXIFYLLINE;

EID: 0034569766     PISSN: 00310808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Jynge P, Hearse DJ, De Leiris J, Feuvray D, Braimbridge MV. Protection of the ischemic myocardium. Ultrastructural, enzymatic and functional assessment of the efficacy of various cardioplegic infusates. J Thorac Cardiovasc Surg 1978;76:2-15.
2. Conti VR, Bertroman EG, Blackstone EH, Kirklin JW, Digerness SB. Cold cardioplegia versus hypothermia for myocardial protection. J Thorac Cardiovasc Surg 1978;76:577-89.
3. Follette DM, Mulder DG, Maloney JV, Buckberg GD. Advantages of blood cardioplegia over continuous coronary perfusion to intermittent ischemia: experimental and clinical study. J Thorac Cardiovasc Surg 1978;76:604-19.
4. Barner HB, Laks H, Codd JE, Standeven JW, Jellinek M, Kaiser GC et al. Cold blood as the vehicle for potassium cardioplegia. Ann Thorac Surg 1979;28:509-21.
5. Taşdemir O, Katircioǧlu SF, Küçükasku D, Göl K, Hayran M, Keçeligil T et al. Warm blood cardioplegia: ultrastructural and hemodynamic study. Ann Thorac Surg 1993;56:305-11.
6. Gallenkamper W, Rücker W, Schrör K. Cardioprotective actions of pentoxyfylline in an animal model of acute myocardial ischemia. Br J Pharmacol 1984;81:575-81.
7. Leonhardt H, Grigoleit HG. Effects of pentoxyphylline on red blood cell deformability and blood viscosity under hyperosmolar conditions. Naunyn Schmiedebergs Arch Pharmacol 1977;299: 197-200.
8. Stefanovich V. Effect of 3,7-dimethyl-1-(5-oxo-hexyl)-xanthine and 1-hexyl-3,7-dimethyl xanthine on cyclic AMP phosphodiesterase of the human umblical cord vessels. Res Commun Chem Pathol Pharmacol 1973;5:655-62.
9. Katircioǧlu SF, Küçükasku D, Bozdayi M, Saydam G, Zorlutuna Y, Taşdemir O et al. Effects of prostacyclin on heparin reversal with protamine. Vase Surg 1992;8:464-72.
10. Matzky R, Darius H, Schror K. The release of prostacyclin (PGI2) by pentoxyphylline from human vascular tissue. Arzneim-Forsch 1982;32:1315-8.
11. Ogletree ML, Lefer AM, Smith JB, Nicolaou KC. Studies on the protective effect of prostacyclin in acute myocardial ischemia. Eur J Pharmacol 1979;56:95-103.
12. Katircioǧlu SF, Küçükasku D, Bozdayi M, Taşdemir O, Bayazit K. Beneficial effects of prostacyclin treatment on reperfusion of the myocardium. Cardiovasc Surg 1995;3:405-8.
13. Katircioǧlu SF, Saritaş, Z, Ulus AT, Yamak B, Yücel D, Ayaz S. Iloprost added to the cardioplegic solutions improves myocardial performance. Postaglandins 1998;55:51-65.
14. Katircioǧlu SF, Ulus AT, Iscan Z, Saritaş, Z, Yalak B, Birincioglu L. Preservation of myocardial metabolism in acute coronary artery occlusions with retrograde coronary sinus perfusion and iloprost. Prostaglandins Leukot Essent Fatty Acids 1998;59:169-74.
15. Rutherford JD, Vatner SF, Braunwald E. Effects of aminophylline in the conscious dog after coronary occlusion. Am J Cardiol 1981;48: 1071-6.